Danaher Corporation $DHR Stock Sold by Howland Capital Management LLC

Howland Capital Management LLC decreased its holdings in Danaher Corporation (NYSE:DHR) by 4.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 166,298 shares of the conglomerate’s stock after selling 7,662 shares during the period. Danaher comprises 1.3% of Howland Capital Management LLC’s portfolio, making the stock its 17th largest holding. Howland Capital Management LLC’s holdings in Danaher were worth $36,910,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Prime Capital Investment Advisors LLC grew its position in Danaher by 0.5% during the third quarter. Prime Capital Investment Advisors LLC now owns 9,203 shares of the conglomerate’s stock valued at $2,039,000 after purchasing an additional 45 shares in the last quarter. Veery Capital LLC increased its stake in Danaher by 3.1% in the 3rd quarter. Veery Capital LLC now owns 1,581 shares of the conglomerate’s stock valued at $350,000 after buying an additional 48 shares during the period. Studio Investment Management LLC increased its stake in Danaher by 3.3% in the 2nd quarter. Studio Investment Management LLC now owns 1,581 shares of the conglomerate’s stock valued at $302,000 after buying an additional 51 shares during the period. OLD Second National Bank of Aurora increased its stake in Danaher by 0.5% in the 1st quarter. OLD Second National Bank of Aurora now owns 12,114 shares of the conglomerate’s stock valued at $2,297,000 after buying an additional 57 shares during the period. Finally, Adelphi Trust Co lifted its position in Danaher by 2.5% in the 3rd quarter. Adelphi Trust Co now owns 2,365 shares of the conglomerate’s stock worth $524,000 after buying an additional 57 shares in the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Stock Performance

Shares of DHR opened at $229.86 on Friday. The company’s fifty day moving average is $215.76 and its 200-day moving average is $197.12. Danaher Corporation has a 12 month low of $160.93 and a 12 month high of $242.80. The firm has a market cap of $161.59 billion, a price-to-earnings ratio of 40.83, a price-to-earnings-growth ratio of 2.95 and a beta of 0.76. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48.

Danaher (NYSE:DHR) last released its quarterly earnings results on Wednesday, October 21st. The conglomerate reported $2.11 earnings per share for the quarter, beating analysts’ consensus estimates of $1.92 by $0.19. Danaher had a net margin of 16.91% and a return on equity of 11.22%. The business had revenue of $6.55 billion for the quarter, compared to the consensus estimate of $6.56 billion. During the same quarter last year, the firm earned $1.89 EPS. Danaher’s revenue for the quarter was up 8.3% on a year-over-year basis. Equities analysts expect that Danaher Corporation will post 8.51 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a $0.40 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. Danaher’s payout ratio is currently 28.42%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Evercore reissued an “outperform” rating and set a $230.00 target price on shares of Danaher in a research note on Monday, July 6th. TD Cowen upped their price target on shares of Danaher from $255.00 to $270.00 and gave the stock a “buy” rating in a research note on Thursday. Weiss Ratings upgraded Danaher from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, September 16th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $240.00 price objective on shares of Danaher in a report on Wednesday, July 22nd. Finally, Citigroup lifted their price objective on Danaher from $230.00 to $270.00 and gave the company a “buy” rating in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $242.91.

Danaher News Roundup

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher reported third-quarter adjusted earnings of $2.11 per share, ahead of the $1.92 analyst consensus, while revenue increased 8.3% year over year to $6.55 billion. Biotechnology profitability and improving demand across several end markets supported the earnings beat. Danaher Beats Profit Estimates, Raises Outlook as Customer Demand Improves
• Positive Sentiment: Management raised its full-year 2026 adjusted EPS outlook to $8.57-$8.62, and biotechnology orders grew at a mid-teens rate. The company also highlighted margin expansion, improving customer demand, and artificial-intelligence capabilities that could support longer-term drug-discovery growth. Danaher: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Several analysts raised their price targets, including TD Cowen and JPMorgan to $270, Goldman Sachs to $275, and Stifel to $260. The upgrades reflect confidence in the earnings beat, improved execution, and the stronger profit outlook.
• Neutral Sentiment: New CEO Julie Montgomery emphasized the need to improve execution and innovation. Investors are watching whether management can convert the company’s AI and biotechnology investments into sustained growth. Danaher Posts First Earnings Under New CEO
• Negative Sentiment: Revenue was approximately in line with, or slightly below, estimates, while analysts cited tariff pressure and a cautious 2027 outlook. At roughly 41 times earnings, Danaher’s valuation leaves limited room for operational disappointment, contributing to the negative investor reaction despite the quarterly beat.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.